利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.024 秒)

    Novel phenoxyaliphatylphenyleneoxyalkyl esters and amides
    2.
    发明授权
    Novel phenoxyaliphatylphenyleneoxyalkyl esters and amides 失效
    新型苯氧基亚芳基苯基氧基烷基酯和酰胺

    公开(公告)号：US4818766A

    公开(公告)日：1989-04-04

    申请号：US75156

    申请日：1987-07-20

    申请人： Franz Ostermayer ,  Markus Zimmermann

    发明人： Franz Ostermayer ,  Markus Zimmermann

    IPC分类号： A61K31/44 ,  A61K31/4427 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P25/02 ,  C07D211/90 ,  C07D401/12 ,  C07D413/12 ,  A61K31/455

    CPC分类号： C07D211/90

    摘要： The invention relates to novel 1,4-dihydropyridine-3-carboxylic acid phenoxyaliphatylphenyleneoxyalkyl esters of the formula ##STR1## in which Ac represents an acyl group, X represents oxy or optionally substituted imino, A represents a divalent aliphatic hydrocarbon radical interrupted by a group --X.sub.1 --Ph--X.sub.2 -- in which at least one of the radicals X.sub.1 and X.sub.2 represents oxy and a radical X.sub.1 or X.sub.2 that is other than oxy represents a direct bond, and Ph represents an optionally substituted phenylene radical, and R represents an optionally substituted phenyl, pyridyl or 1-oxidopyridyl, (1,3-dioxa)indanyl or benzofurazanyl radical, R.sub.1 represents an optionally substituted phenyl or indolyl radical, R.sub.2 represents an aliphatic hydrocarbon radical and R.sub.3 represents an aliphatic radical, cyano or amino, and acid addition salts thereof.

    摘要翻译： 本发明涉及式（Ⅰ）的新颖的1,4-二氢吡啶-3-羧酸苯氧基苯基苯基氧基烷基酯，其中Ac代表酰基，X代表氧基或任意取代的亚氨基，A代表二价脂族烃基中断 基团-X1-Ph-X2-，其中基团X1和X2中的至少一个表示氧，并且除氧以外的基团X 1或X 2表示直接键，并且Ph表示任选取代的亚苯基，R 表示任选取代的苯基，吡啶基或1-氧化吡啶基，（1,3-二氧杂）茚满基或苯并呋喃基，R1表示任选取代的苯基或吲哚基，R 2表示脂族烃基，R 3表示脂族基，氰基或氨基 ，及其酸加成盐。

    N-Alkylated aminoalcohols and their pharmaceutical compositions useful for the treatment of cardiac insufficiency
    5.
    发明授权
    N-Alkylated aminoalcohols and their pharmaceutical compositions useful for the treatment of cardiac insufficiency 失效
    N-烷基化氨基醇及其用于治疗心功能不全的药物组合物

    公开(公告)号：US4460580A

    公开(公告)日：1984-07-17

    申请号：US391814

    申请日：1982-06-24

    申请人： Franz Ostermayer ,  Markus Zimmermann

    发明人： Franz Ostermayer ,  Markus Zimmermann

    IPC分类号： A61K31/165 ,  A61P9/04 ,  A61P25/02 ,  C07C67/00 ,  C07C229/38 ,  C07C231/00 ,  C07C231/12 ,  C07C231/14 ,  C07C235/46 ,  C07C237/30 ,  C07D213/38 ,  C07D265/22 ,  C07D307/52 ,  C07D333/20 ,  C07D213/56 ,  A61K31/44

    CPC分类号： C07D265/22 ,  C07C229/38 ,  C07D213/38 ,  C07D307/52 ,  C07D333/20

    摘要： The invention relates to novel N-alkylated aminoalcohols of the formula ##STR1## in which Ar is a radical of aromatic character which is unsubstituted or substituted by hydroxyl, n has the values nought or 1 and Alk is an alkylene radical having 2 to 5 carbon atoms and the nitrogen atom and the oxygen atom or, if n is nought, the salicylamide radical are separated from one another by at least two carbon atoms in the straight-chain, and their salts. The main action of the novel compounds consists in a stimulation of cardiac .beta.-receptors; the compounds also effect a blockage of adrenergic .alpha.-receptors and a lowering in the blood pressure. They can therefore be used as .beta.-stimulators, especially as agents having a positively inotropic action for the treatment of cardiac insufficiency. Compounds of the formula I in which Ar is phenyl, unsubstituted or substituted by 1 or 2 hydroxyl groups, Alk is an alkylene radical having 2 to 4 carbon atoms, n has the value 1, and the nitrogen atom and the oxygen atom are separated from one another by at least 2 carbon atoms in the straight-chain, or salts thereof, exhibit effects on the central nervous system, which are reflected for example in the suppression of the symptoms of impaired sympathetic functions and in the suppression of lack of initiative. Such compounds of the formula I therefore can be used for the treatment of reactive or endogenic states of depression of varying degrees of severity, and also for the treatment of neurotic or other psychic disturbances involving loss of initiative and depressive disorders. Such compounds can also be used for the short-term treatment of post-partum or postoperative depression, or of depression of different origin. Such compounds of the formula I can be used on their own or in combination with other antidepressants.

    摘要翻译： 本发明涉及式（I）的新型N-烷基化氨基醇，其中Ar是未被取代或被羟基取代的芳族基团，n的值不为1，Alk为具有2个的亚烷基 至5个碳原子和氮原子和氧原子，或者如果n无效，则水杨酰胺基团通过直链中的至少两个碳原子和它们的盐彼此分离。 新化合物的主要作用在于刺激心脏β受体; 该化合物还会影响肾上腺素α受体的阻断和降低血压。 因此，它们可以用作β-刺激剂，特别是作为具有正性肌力作用的药物用于治疗心功能不全。 其中Ar为未取代或被1或2个羟基取代的苯基的式I化合物，Alk为碳原子数2〜4的亚烷基，n为1，氮原子和氧原子与 直链中至少有2个碳原子或其盐，彼此之间呈现对中枢神经系统的作用，例如反映在抑制交感神经功能受损症状和抑制缺乏主动性的作用。 因此，式I的这种化合物可用于治疗不同程度的严重程度的抑郁症的反应性或内源性状态，并且还可用于治疗涉及主动性和抑郁障碍丧失的神经质或其他心理障碍。 这些化合物也可用于短期治疗产后或术后抑郁症或不同来源的抑郁症。 式I化合物可以单独使用或与其它抗抑郁药组合使用。

    Piperidino-propanols
    7.
    发明授权
    Piperidino-propanols 失效
    哌哌啶 - 丙醇

    公开(公告)号：US4264599A

    公开(公告)日：1981-04-28

    申请号：US921521

    申请日：1978-07-03

    申请人： Kurt Eichenberger ,  Hans Kuhnis ,  Franz Ostermayer ,  Herbert Schroter

    发明人： Kurt Eichenberger ,  Hans Kuhnis ,  Franz Ostermayer ,  Herbert Schroter

    IPC分类号： C07D209/08 ,  C07D211/58 ,  C07D213/65 ,  C07D213/69 ,  C07D401/14 ,  A61K31/365 ,  A61K31/495

    CPC分类号： C07D213/69 ,  C07D209/08 ,  C07D211/58 ,  C07D213/65

    摘要： The invention relates to novel piperidino-propanols, especially 1-(3-heterocyclyloxy-2-hydroxy-propanol)-4-(N-diazcyclyl)-piperidines of the formula ##STR1## in which R.sub.1 is a substituted or unsubstituted heteroaryl radical, R.sub.2 is hydrogen or a substituted or unsubstituted aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic hydrocarbon radical or an acyl radical and alk is lower alkylene which separates the two nitrogen atoms from one another by 2 or 3 carbon atoms, or is a substituted or unsubstituted 1,2-phenylene radical, and salts thereof, as well as processes for their preparation, and also to pharmaceutical preparations containing these compounds and the use thereof, preferably in the form of pharmaceutical preparations as antihypertensive agents, antitachycardiac agents and .alpha.-sympathicolytic agents.

    摘要翻译： 本发明涉及新的哌啶子基 - 丙醇，特别是式（I）的1-（3-杂环氧基-2-羟基 - 丙醇）-4-（N-二氮杂环丙基） - 哌啶，其中R 1是取代或未取代的 杂芳基，R2是氢或取代或未取代的脂族，脂环族，脂环族 - 脂族或芳脂族烃基或酰基，而烷基是两个氮原子彼此分开2或3个碳原子的低级亚烷基，或者是 取代或未取代的1,2-亚苯基及其盐，以及其制备方法，以及含有这些化合物的药物制剂及其用途，优选以药物制剂的形式作为抗高血压药，抗心律失常药和α - 溶脂剂。

    Pyrrolyl compounds and processes for their manufacture
    9.
    发明授权
    Pyrrolyl compounds and processes for their manufacture 失效
    吡咯基化合物及其制备方法

    公开(公告)号：US3984436A

    公开(公告)日：1976-10-05

    申请号：US447118

    申请日：1974-02-28

    申请人： Knut A. Jaeggi ,  Franz Ostermayer ,  Herbert Schroter

    发明人： Knut A. Jaeggi ,  Franz Ostermayer ,  Herbert Schroter

    IPC分类号： C07D207/06 ,  A61K31/40 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P25/00 ,  A61P25/02 ,  C07D207/32 ,  C07D207/325

    CPC分类号： C07D207/325 ,  Y10S514/821

    摘要： Pyrrolyl compounds of the formula I ##EQU1## wherein Py is optionally lower-alkylated 1-pyrrolyl, Ph is phenylene, R.sub.1 is hydrogen or lower alkyl and R.sub.2 is hydrogen, lower alkyl, aryl-lower alkyl or optionally functionally modified carboxy-lower alkyl or R.sub.1 and R.sub.2 together are lower alkylene, oxa-lower alkylene, thia-lower alkylene or aza-lower alkylene, their antipodes and salts, which are valuable blockers of adrenergic .beta.-receptors.

    摘要翻译： 式I的吡咯基化合物R1 Py-Ph-O-CH2-CHOH-CH2-N（I）R2 R1 Py-Ph-O-CH2-CHOH-CH2-N（I）R2其中Py是任选低级 - 烷基化的1-吡咯基，Ph是亚苯基，R 1是氢或低级烷基，R 2是氢，低级烷基，芳基 - 低级烷基或任选的官能改性的羧基 - 低级烷基或R 1和R 2一起是低级亚烷基，氧杂低级亚烷基，硫杂 - 低级亚烷基或氮杂 - 低级亚烷基，它们的对映体和盐，它们是肾上腺素β受体的有价值的阻断剂。

    Acyl compounds
    10.
    发明授权
    Acyl compounds 失效
    酰基化合物

    公开(公告)号：US5399578A

    公开(公告)日：1995-03-21

    申请号：US998755

    申请日：1992-12-29

    申请人： Peter Buhlmayer ,  Franz Ostermayer ,  Tibur Schmidlin

    发明人： Peter Buhlmayer ,  Franz Ostermayer ,  Tibur Schmidlin

    IPC分类号： A61K31/195 ,  A61K31/41 ,  A61K31/44 ,  A61K31/47 ,  A61K31/535 ,  A61K31/675 ,  A61P9/12 ,  C07C229/38 ,  C07C231/00 ,  C07C233/47 ,  C07C233/51 ,  C07C233/54 ,  C07C235/04 ,  C07C271/10 ,  C07C311/48 ,  C07D233/54 ,  C07D233/58 ,  C07D233/64 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/00 ,  C07D405/00 ,  C07D409/00 ,  C07F9/6524

    CPC分类号： C07D233/64 ,  C07C229/38 ,  C07C233/54 ,  C07D257/04 ,  C07D401/12

    摘要： Compounds of the formula ##STR1## in which R.sub.1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X.sub.1 is CO, SO.sub.2, or --O--C(.dbd.O)-- with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X.sub.2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R.sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O).sub.m --R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO.sub.n H.sub.2 where n is 2 or 3; X.sub.3 is a divalent aliphatic hydrocarbon; R.sub.3 is carboxyl, 5-tetrazolyl, SO.sub.3 H, PO.sub.2 H.sub.2, PO.sub.3 H.sub.2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.

    摘要翻译： 式（I）的化合物，其中R 1是未被取代或被卤素或羟基取代的脂族烃基，或脂环族或芳脂族烃基; X 1是CO，SO 2或-O-C（= O） - ，其中羰基的碳原子连接到式I所示的氮原子上; X2是未取代的或被羟基，羧基，氨基，胍基或脂环族或芳族基团取代的二价脂族烃基，或者是二价脂环族烃基，脂族烃基的碳原子可能另外 由二价脂族烃基桥连; R 2是羧基，如果需要，其被酯化或酰胺化，取代或未取代的氨基，如果需要，缩醛化的甲酰基，1H-四唑-5-基，吡啶基，羟基，如果需要，其醚化，S（O） mR，其中m为0,1或2，R为氢或脂族烃基，烷酰基，未取代的或N-取代的氨磺酰基或POnH 2，其中n为2或3; X3是二价脂族烃; R3是羧基，5-四唑基，SO3H，PO2H2，PO3H2或卤代烷基氨磺酰; 环A和B彼此独立地是取代或未取代的; 游离形式或盐形式可以以本身已知的方式制备，并且可以用作例如药物活性成分。